Results 201 to 210 of about 22,035 (254)

Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers.

International journal of pharmaceutics, 2021
The present study was designed to investigate the contribution of solid-state and the impact of composite drug-rich phase generated as a consequence of pH shift on the maximum achievable supersaturation of co-amorphous formulations.
Sushant Shete, S. C. Reddy, Yarlagadda Dani Lakshman, Sai Krishna Anand Vullendula, C. Mehta, U. Nayak, S. Dengale   +6 more
semanticscholar   +1 more source

Optimization of the Synthetic Parameters of Lipid Polymer Hybrid Nanoparticles Dual Loaded with Darunavir and Ritonavir for the Treatment of HIV.

International journal of pharmaceutics, 2020
Human Immunodeficiency Virus (HIV) is a global health concern to which nanomedicine approaches provide opportunities to improve the bioavailability of existing drugs used to treat HIV.In this article, lipid polymer hybrid nanoparticles (LPHNs) were ...
H. Elkateb, Lee M. Tatham, Helen Cauldbeck, Edyta Niezabitowska, A. Owen, S. Rannard, Tom O. McDonald   +6 more
semanticscholar   +1 more source

Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.

Journal of Pharmaceutical and Biomedical Analysis, 2021
Dolutegravir, raltegravir and darunavir are three antiretroviral drugs widely used in combined antiretroviral therapies. These three drugs are highly bound to plasma proteins.
Yi Zheng, Gabrielle Lui, S. Boujaafar, R. Aboura, N. Bouazza, F. Foissac, J. Treluyer, S. Benaboud, D. Hirt, I. Gana   +9 more
semanticscholar   +1 more source

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

The Lancet HIV, 2019
BACKGROUND Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults with HIV who were treatment naive at week 48 in the phase 3 ...
J. Molina, K. Squires, P. Sax, P. Cahn, J. Lombaard, E. Dejesus, M. Lai, A. Rodgers, L. Lupinacci, Sushma Kumar, P. Sklar, G. Hanna, C. Hwang, E. Martin   +13 more
semanticscholar   +1 more source

Clinical Pharmacokinetics of Darunavir

Clinical Pharmacokinetics, 2007
Darunavir (TMC114) is a newly developed HIV-1 protease inhibitor with potent antiviral activity against both wild-type and multidrug resistant HIV-1 strains. The drug is currently approved by the US FDA for antiretroviral treatment-experienced patients with limited therapeutic options.
Michael, Rittweger, Keikawus, Arastéh
openaire   +2 more sources

Stability and Mechanical Properties of Darunavir Isostructural Solvates: An Experimental and Computational Study

Crystal Growth & Design, 2023
Kaxi Yu, Jie Shen, Jiyong Liu, Guping Tang, Xiurong Hu   +4 more
semanticscholar   +1 more source

Darunavir

Reactions Weekly, 2022
openaire   +2 more sources

Darunavir

Drugs of the Future, 2005
null Sorbera, L.A., null Castaner, J., null Bayes, M.   +2 more
openaire   +1 more source

Darunavir

Reactions Weekly, 2020
openaire   +1 more source

Darunavir

Reactions Weekly, 2009
openaire   +2 more sources